Therapeutic potency of Nrf2, a key antioxidative transcription factor, for pulmonary hypertension
Project/Area Number |
23592052
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Thoracic surgery
|
Research Institution | Tohoku University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
KONDO Takashi 東北大学, 加齢医学研究所, 教授 (10195901)
FUKUMOTO Yoshihiro 久留米大学, 医学部, 教授 (70363372)
NODA Masafumi 東北大学, 大学病院, 講師 (70400356)
OKADA Yoshinori 東北大学, 加齢医学研究所, 准教授 (90323104)
|
Project Period (FY) |
2011 – 2013
|
Project Status |
Completed (Fiscal Year 2013)
|
Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2011: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
Keywords | 肺高血圧症 / 酸化ストレス / Nrf2 / 遺伝子改変マウス / 低酸素曝露 / 慢性呼吸器疾患 / 低酸素 / 肺高血圧 / 肺血管リモデリング / tenascin-C / 右心室肥大 / CD31陽性 / 活性化剤 |
Research Abstract |
Three weeks of hypoxia exacerbated pulmonary hypertension (PH), right ventricular hypertrophy (RVH), and pulmonary vascular remodeling in mice. These pathological changes were associated with aberrant accumulation of a extracellular glycoprotein, Tenascin-C. Both administration of oltipraz, a potent Nrf2 activator, and Keap1 (negative regulator of Nrf2) knockdown significantly attenuated RVH and pulmonary vascular remodeling and concomitantly ameliorated Tenascin-C accumulation in the hypoxic mouse lungs. Expression of the Nrf2-regulated antioxidant enzymes was decreased in a patient with chronic obstructive pulmonary disease associated with PH. The decreased antioxidant enzymes may underlie the pathogenesis of cardiopulmonary changes in the patient with chronic obstructive pulmonary disease and PH. The efficacy of oltipraz highlights a promising therapeutic potency of Nrf2 activators for the prevention of PH in patients with hypoxemic lung disease.
|
Report
(4 results)
Research Products
(14 results)
-
[Journal Article] The nuclear factor erythroid 2-related factor 2 activator oltipraz attenuates chronic hypoxia-induced cardiopulmonary alterations in mice.2013
Author(s)
Eba S, Hoshikawa Y, Moriguchi T, Mitsuishi Y, Satoh H, Ishida K, Watanabe T, Shimizu T, Shimokawa H, Okada Y, Yamamoto M, Kondo T
-
Journal Title
Am J Respir Cell Mol Biol
Volume: 49(2
Issue: 2
Pages: 324-333
DOI
Related Report
Peer Reviewed
-
[Journal Article] The Nrf2 Activator Oltipraz Attenuates Chronic Hypoxia-Induced Cardiopulmonary Alterations In Mice.2013
Author(s)
Eba S, Hoshikawa Y, Moriguchi T, Mitsuishi Y, Satoh H, Ishida K, Watanabe T, Shimizu T, Shimokawa H, Okada Y, Yamamoto M, Kondo T
-
Journal Title
Am J Respir Cell Mol Biol.
Volume: in press
Related Report
Peer Reviewed
-
[Presentation] Activation of NRF2 Attenuates Hypoxia-induced Cardiopulmonary Alterations in Mice2012
Author(s)
S. Eba, Y. Hoshikawa, T. Moriguchi, Y. Mitsuishi, H. Sato, K. Ishida, T. Watanabe, Y. Okada, M. Yamamoto, T. Kondo
Organizer
Aspen Lung Conference
Place of Presentation
Aspen, CO, USA.
Year and Date
2012-06-07
Related Report
-
[Presentation] Activation Of Nrf2 Attenuates Hypoxia-Induced Cardiopulmonary Alterations In Mice2012
Author(s)
S. Eba, Y. Hoshikawa, T. Moriguchi, Y. Mitsuishi, H. Sato, T. Watanabe, Y. Watanabe, Y. Okada, T. Kondo
Organizer
American Thoracic Society International Conference 2012
Place of Presentation
San Francisco, CA, USA
Year and Date
2012-05-20
Related Report
-
-
[Presentation] 肺高血圧病態における抗酸化ストレス転写因子Nrf2の役割の検討2012
Author(s)
江場俊介,星川康光,石陽一郎,渡邊龍秋,川村昌輝,石橋直也,渡辺有為,野津田泰嗣,鈴木隆哉,大石久,前田寿美子,野田雅史顕,岡田克典,佐渡哲,桜田晃,遠藤千,山本雅之,近藤丘
Organizer
White Conference 2012
Place of Presentation
軽井沢
Year and Date
2012-01-21
Related Report
-
[Presentation] Activation Of Nrf2 Attenuates Hypoxia-Induced Cardiopulmonary Alterations In Mice2012
Author(s)
S. Eba, Y. Hoshikawa, T. Moriguchi, Y. Mitsuishi, H. Sato, T. Watanabe, Y. Watanabe, Y. Okada, T. Kondo
Organizer
2012 American Thoracic Society International Conference
Place of Presentation
San Francisco, CA, U.S.A.
Related Report
-
[Presentation] ACTIVATION OF NRF2 ATTENUATES HYPOXIA-INDUCED CARDIOPULMONARY ALTERATIONS IN MICE.2012
Author(s)
S. Eba, Yasushi Hoshikawa*, T. Moriguchi, Y. Mitsuishi, H. Sato, K. Ishida, T. Watanabe, Y. Okada, M. Yamamoto, T. Kondo
Organizer
Aspen Lung Conference
Place of Presentation
Aspen, CO, U.S.A.
Related Report
-
-
[Presentation] Nrf2活性化剤oltiprazの長期低酸素曝露による心肺病変抑制効果2011
Author(s)
江場俊介,星川康光,石陽一郎,渡邊龍秋,川村昌輝,石橋直也,渡辺有為,野津田泰嗣,鈴木隆哉,大石久,前田寿美子,野田雅史顕,岡田克典,佐渡哲,桜田晃,遠藤千,近藤丘
Organizer
iPUC (integrated Pulmonary Circulation Research)-II
Place of Presentation
東京
Year and Date
2011-06-25
Related Report
-
[Presentation] An Nrf2 Activator, Oltipraz Attenuates Chronic Hypoxia-induced Cardiopulmonary Alterations in Mice2011
Author(s)
S Eba, Y Hoshikawa, Y Mitsuishi, H Sato, T Watanabe, Y Watanabe, S Maeda, Y Okada, T Kondo
Organizer
American Thoracic Society International Conference 2011
Place of Presentation
Denver, Colorado, USA
Year and Date
2011-05-11
Related Report
-
-
[Presentation] An Nrf2 Activator, Oltipraz Attenuates Chronic Hypoxia-induced Cardiopulmonary Alterations in Mice
Author(s)
S Eba, Y Hoshikawa, Y Mitsuishi, H Sato, T Watanabe, Y Watanabe, S Maeda, Y Okada, T Kondo
Organizer
American Thoracic Society International Conference 2012
Place of Presentation
Denver, Colorado, USA
Related Report
-